bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Figure 2 from Therapeutic Potential of HSP90 Inhibition for Neurofibromatosis Type 2
Authors: Tanaka Karo , Eskin Ascia , Chareyre Fabrice , Jessen Walter J. , Manent Jan , Niwa-Kawakita Michiko , Chen Ruihong , White Cory H. , Vitte Jeremie , Jaffer Zahara M. , Nelson Stanley F. , Rubenstein Allan E. , Giovannini Marco
Published: April 2023

Supplementary Figure 2 - PDF files 4552K, Global transcriptome profiling of NXD30001 efficacy
Supplementary Figure 1 from Therapeutic Potential of HSP90 Inhibition for Neurofibromatosis Type 2
Authors: Tanaka Karo , Eskin Ascia , Chareyre Fabrice , Jessen Walter J. , Manent Jan , Niwa-Kawakita Michiko , Chen Ruihong , White Cory H. , Vitte Jeremie , Jaffer Zahara M. , Nelson Stanley F. , Rubenstein Allan E. , Giovannini Marco
Published: April 2023

Supplementary Figure 1 - PDF files 5795K, Induction of apoptosis by NXD30001 in NF2-deficient cells
Supplementary Figure 1 from PI3K Pathway Activation in High-Grade Ductal Carcinoma In Situ—Implications for Progression to Invasive Breast Carcinoma
Authors: Sakr Rita A. , Weigelt Britta , Chandarlapaty Sarat , Andrade Victor P. , Guerini-Rocco Elena , Giri Dilip , Ng Charlotte K.Y. , Cowell Catherine F. , Rosen Neal , Reis-Filho Jorge S. , King Tari A.
Published: April 2023

PDF file - 226KB, Representative micrographs of DCIS and invasive breast cancers displaying PTEN expression (A, left) or loss (A, right), INPP4B expression (B, left) or loss (B right), pAKT expression lack of expression (C, left) and pAKT expression in neoplastic cells (C, right), pS6 lack of expression (D, left) and pS6 expression in neoplastic cells (D, right). Please note that in A and B, the expression of PTEN and INPP4B in stromal cells and/or normal breast epithelium was employed as an internal positive control in cases lacking PTEN and INPP4B expression in neoplastic cells, respectively.
Supplementary Tables 1-5 from Impact of c-MYC Protein Expression on Outcome of Patients with Early-Stage HER2+ Breast Cancer Treated with Adjuvant Trastuzumab NCCTG (Alliance) N9831
Authors: Dueck Amylou C. , Reinholz Monica M. , Geiger Xochiquetzal J. , Tenner Kathleen , Ballman Karla , Jenkins Robert B. , Riehle Darren , Chen Beiyun , McCullough Ann E. , Davidson Nancy E. , Martino Silvana , Sledge George W. , Kaufman Peter A. , Kutteh Leila A. , Gralow Julie , Harris Lyndsay N. , Ingle James N. , Lingle Wilma L. , Perez Edith A.
Published: April 2023

Supplementary Tables 1-5 - PDF file 91K, Supplementary Table 1. Patient Characteristics by IHC cMYC Cohort vs Non-Cohort; Supplementary Table 2. Correlation of MYC Nuclear Staining with HER2 FISH - Overall; Supplementary Table 3. Correlation of MYC Nuclear Staining with HER2 FISH - Arm A; Supplementary Data Table 4. Correlation of MYC Nuclear Staining with HER2 FISH - Arm B; Supplementary Table 5. Correlation of MYC Nuclear Staining with HER2 FISH - Arm C
Supplementary Table SIV from Targeting Small Cell Lung Cancer Harboring PIK3CA Mutation with a Selective Oral PI3K Inhibitor PF-4989216
Authors: Walls Marlena , Baxi Sangita M. , Mehta Pramod P. , Liu Kevin K.-C. , Zhu JinJiang , Estrella Heather , Li Chunze , Zientek Michael , Zong Qing , Smeal Tod , Yin Min-Jean
Published: April 2023

XLS file 25K, Supplementary Table IV: PF-4989216 IC50 values for the phosphorylation of AKT in a variety of SCLC lines
Supplementary Table SIII from Targeting Small Cell Lung Cancer Harboring PIK3CA Mutation with a Selective Oral PI3K Inhibitor PF-4989216
Authors: Walls Marlena , Baxi Sangita M. , Mehta Pramod P. , Liu Kevin K.-C. , Zhu JinJiang , Estrella Heather , Li Chunze , Zientek Michael , Zong Qing , Smeal Tod , Yin Min-Jean
Published: April 2023

XLS file 26K, Supplementary Table SIII: Cell cycle population percentages in SCLC lines treated with PF-4989216 with or without the presence of a pan-caspase inhibitor, Z-VAD (OMe) FMK (10 μM)
Supplementary Table SII from Targeting Small Cell Lung Cancer Harboring PIK3CA Mutation with a Selective Oral PI3K Inhibitor PF-4989216
Authors: Walls Marlena , Baxi Sangita M. , Mehta Pramod P. , Liu Kevin K.-C. , Zhu JinJiang , Estrella Heather , Li Chunze , Zientek Michael , Zong Qing , Smeal Tod , Yin Min-Jean
Published: April 2023

XLS file 24K, Supplementary Table SII: Cell cycle population percentages in SCLC lines after PF- 4989216 treatment for 24, 48, and 72 hours
Supplementary Table SI from Targeting Small Cell Lung Cancer Harboring PIK3CA Mutation with a Selective Oral PI3K Inhibitor PF-4989216
Authors: Walls Marlena , Baxi Sangita M. , Mehta Pramod P. , Liu Kevin K.-C. , Zhu JinJiang , Estrella Heather , Li Chunze , Zientek Michael , Zong Qing , Smeal Tod , Yin Min-Jean
Published: April 2023

Supplementary Table SI XLS file 19K, Supplementary Table SI: Kinase selectivity of PF-4989216
Supplementary Tables 1 - 2, Figure 1 from A Dose-Escalation Study of SAR3419, an Anti-CD19 Antibody Maytansinoid Conjugate, Administered by Intravenous Infusion Once Weekly in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Authors: Ribrag Vincent , Dupuis Jehan , Tilly Herve , Morschhauser Franck , Laine Fabrice , Houot Roch , Haioun Corinne , Copie Christiane , Varga Andrea , Lambert John , Hatteville Laurence , Ziti-Ljajic Samira , Caron Anne , Payrard Sandrine , Coiffier Bertrand
Published: April 2023

PDF file - 224K, Supplemental table 1: Mean (CV%) PK parameters of SAR3419 at 55 mg/m2 obtained after first and last administration. Supplemental figure 1: SAR3419 Ctrough observed during repeated intravenous infusion of SAR3419 using weekly or optimized schedules. Supplemental table 2: relationship between CD19 expression, proliferation (KI67), mitosis (pHH3) and p53 status with observed observed responses at the MTD during the optimized schedule.
Supplementary Table 6 and Figure from Unique DNA Methylation Loci Distinguish Anatomic Site and HPV Status in Head and Neck Squamous Cell Carcinoma
Authors: Lleras Roberto A. , Smith Richard V. , Adrien Leslie R. , Schlecht Nicolas F. , Burk Robert D. , Harris Thomas M. , Childs Geoffrey , Prystowsky Michael B. , Belbin Thomas J.
Published: April 2023

PDF file, 231K, Sequenom validation of hypermethylation and hypomethylation.
Legend from Targeting Small Cell Lung Cancer Harboring PIK3CA Mutation with a Selective Oral PI3K Inhibitor PF-4989216
Authors: Walls Marlena , Baxi Sangita M. , Mehta Pramod P. , Liu Kevin K.-C. , Zhu JinJiang , Estrella Heather , Li Chunze , Zientek Michael , Zong Qing , Smeal Tod , Yin Min-Jean
Published: April 2023

PDF file 104K, Legend
Supplementary Table 2 from Tumor Genetic Analyses of Patients with Metastatic Melanoma Treated with the BRAF Inhibitor Dabrafenib (GSK2118436)
Authors: Nathanson Katherine L. , Martin Anne-Marie , Wubbenhorst Bradley , Greshock Joel , Letrero Richard , D'Andrea Kurt , O'Day Steven , Infante Jeffrey R. , Falchook Gerald S. , Arkenau Hendrik-Tobias , Millward Michael , Brown Michael P. , Pavlick Anna , Davies Michael A. , Ma Bo , Gagnon Robert , Curtis Martin , Lebowitz Peter F. , Kefford Richard , Long Georgina V.
Published: April 2023

Supplementary Table 2 - PDF file 42K, Correlation of PTEN immunohistochemistry and PTEN mutation/copy number status
Supplementary Table 1 from Tumor Genetic Analyses of Patients with Metastatic Melanoma Treated with the BRAF Inhibitor Dabrafenib (GSK2118436)
Authors: Nathanson Katherine L. , Martin Anne-Marie , Wubbenhorst Bradley , Greshock Joel , Letrero Richard , D'Andrea Kurt , O'Day Steven , Infante Jeffrey R. , Falchook Gerald S. , Arkenau Hendrik-Tobias , Millward Michael , Brown Michael P. , Pavlick Anna , Davies Michael A. , Ma Bo , Gagnon Robert , Curtis Martin , Lebowitz Peter F. , Kefford Richard , Long Georgina V.
Published: April 2023

Supplementary Table 1 - PDF file 54K, Patient description with tumor PTEN status available
Supplementary Table 2 from BET Bromodomain Inhibition of MYC-Amplified Medulloblastoma
Authors: Bandopadhayay Pratiti , Bergthold Guillaume , Nguyen Brian , Schubert Simone , Gholamin Sharareh , Tang Yujie , Bolin Sara , Schumacher Steven E. , Zeid Rhamy , Masoud Sabran , Yu Furong , Vue Nujsaubnusi , Gibson William J. , Paolella Brenton R. , Mitra Siddhartha S. , Cheshier Samuel H. , Qi Jun , Liu Kun-Wei , Wechsler-Reya Robert , Weiss William A. , Swartling Fredrik J. , Kieran Mark W. , Bradner James E. , Beroukhim Rameen , Cho Yoon-Jae
Published: April 2023

PDF file - 66K, A, Primers used for qPCR assays B, MYC gene sets in GSEA.
Supplementary Table 1 from BET Bromodomain Inhibition of MYC-Amplified Medulloblastoma
Authors: Bandopadhayay Pratiti , Bergthold Guillaume , Nguyen Brian , Schubert Simone , Gholamin Sharareh , Tang Yujie , Bolin Sara , Schumacher Steven E. , Zeid Rhamy , Masoud Sabran , Yu Furong , Vue Nujsaubnusi , Gibson William J. , Paolella Brenton R. , Mitra Siddhartha S. , Cheshier Samuel H. , Qi Jun , Liu Kun-Wei , Wechsler-Reya Robert , Weiss William A. , Swartling Fredrik J. , Kieran Mark W. , Bradner James E. , Beroukhim Rameen , Cho Yoon-Jae
Published: April 2023

PDF file - 72K, Nanostring CNV of MB002 and MB004.
Supplementary Figure 1 from BET Bromodomain Inhibition of MYC-Amplified Medulloblastoma
Authors: Bandopadhayay Pratiti , Bergthold Guillaume , Nguyen Brian , Schubert Simone , Gholamin Sharareh , Tang Yujie , Bolin Sara , Schumacher Steven E. , Zeid Rhamy , Masoud Sabran , Yu Furong , Vue Nujsaubnusi , Gibson William J. , Paolella Brenton R. , Mitra Siddhartha S. , Cheshier Samuel H. , Qi Jun , Liu Kun-Wei , Wechsler-Reya Robert , Weiss William A. , Swartling Fredrik J. , Kieran Mark W. , Bradner James E. , Beroukhim Rameen , Cho Yoon-Jae
Published: April 2023

PDF file - 567K, A, Gene expression sub-group profiling of MB002 and MB004 patient-derived medulloblastoma cell lines. B, Western blot (left) and densitometry of western blot (right) depicting MYC expression relative to β actin loading control in patient derived medulloblastoma cell lines. ** depict cell lines which are known to harbor amplification of MYC.
Supplementary Figure 5 from T Lymphocytes Redirected against the Chondroitin Sulfate Proteoglycan-4 Control the Growth of Multiple Solid Tumors both In Vitro and In Vivo
Authors: Geldres Claudia , Savoldo Barbara , Hoyos Valentina , Caruana Ignazio , Zhang Ming , Yvon Eric , Del Vecchio Michele , Creighton Chad J. , Ittmann Michael , Ferrone Soldano , Dotti Gianpietro
Published: April 2023

PDF file - 94K, Expansion and antitumor activity of T cells expressing a second versus a third generation CAR.CSPG4. Panel A illustrates the expansion of control, CAR.CSPG4 (2nd gen, CD28 costimulation), and CAR.CSPG4 (3rd gen, CD28/4-1BB costimulation) within 14 days of culture. Data represents the average of 4 T-cell lines with mean � SD. Panel B. Summary of co-culture experiments of anti-tumor activity of control, CAR.CSPG4+ T cells either 2nd or 3rd generation against a panel of CSPG4+ tumor targets. Data represent averages of 3 donors with mean � SD. * = p<0.05, and *** = p<0.001.
Supplementary Figure 4 from T Lymphocytes Redirected against the Chondroitin Sulfate Proteoglycan-4 Control the Growth of Multiple Solid Tumors both In Vitro and In Vivo
Authors: Geldres Claudia , Savoldo Barbara , Hoyos Valentina , Caruana Ignazio , Zhang Ming , Yvon Eric , Del Vecchio Michele , Creighton Chad J. , Ittmann Michael , Ferrone Soldano , Dotti Gianpietro
Published: April 2023

PDF file - 152K, Comparison of CAR.CSPG4+ and CAR.CD19+ T lymphocytes. Panel A. Expression of CAR.CD19 and CAR.CSPG4 in T lymphocytes after retroviral transduction, as assessed by FACS. Panel B. Co-culture experiments in which CAR.CSPG4+ T cells, CAR.CD19+ T cells, and control (non-transduced) cells were cultured with GFP+ tumor cell lines. Pictures illustrate the elimination of CSPG4+eGFP+ target (SENMA) by CAR.CSPG4+ T cells and not by CAR.CD19+ T cells or control T cells after 72 hours of co-culture. The CSPG4- cell lines P1143 was not targeted by either CAR.CSPG4+ T cells or CAR.CD19+ T cells. Panel C. Proliferation of control (non-transduced), CAR.CD19+, and CAR.CSPG4+ T cells upon stimulation with CSPG4+ target in a 96 hour CFSE dilution assay. Data are representative of three independent experiments using irradiated SENMA tumor cells. Panel D. Control (non transduced), CAR.CD19+, and CAR.CSPG4+ T cells were evaluated in a 6 hour cytotoxicity assay against SENMA (CSPG4+), K562 (natural killer cell target), and P1143 (CSPG4-). Data represents the average of three experiments with mean � SD.
Supplementary Methods, Tables 1 - 6, Figures 1 - 6 from NIK Controls Classical and Alternative NF-κB Activation and Is Necessary for the Survival of Human T-cell Lymphoma Cells
Authors: Odqvist Lina , Sánchez-Beato Margarita , Montes-Moreno Santiago , Martín-Sánchez Esperanza , Pajares Raquel , Sánchez-Verde Lydia , Ortiz-Romero Pablo L. , Rodriguez Jose , Rodríguez-Pinilla Socorro M. , Iniesta-Martínez Francisca , Solera-Arroyo Juan Carlos , Ramos-Asensio Rafael , Flores Teresa , Palanca Javier Menarguez , Bragado Federico García , Franjo Purificación Domínguez , Piris Miguel A.
Published: April 2023

PDF file - 1756K, Supplementary Materials and Methods; Table S1: Antibodies and conditions for immunohistochemistry; Table S2: Multivariate Cox analysis; Table S3: Immunohistochemical staining of NF-κB in T cell lymphoma cell lines; Table S4: Pathways positively correlated with NIK expression in PTCL; Table S5: Gene Sets enriched in control cells after NIK knockdown in MyLa and SR-786 cells; Table S6: Genes with altered expression after NIK knockdown; Figure S1: Overall survival in PTCL-NOS and AITL; Figure S2: p100 and p105 levels after NIK knockdown; Figure S3: Cell cycle alterations induced by NIK knockdown; Figure S4: Knockdown of IKKα and IKKβ in SR-786; Figure S5: Efficiencies of NIK knockdown; Figure S6: IL6 and IL21 levels in PTCL cell lines.
Legends of Supplementary Figures and Tables from Molecular Classification of Malignant Pleural Mesothelioma: Identification of a Poor Prognosis Subgroup Linked to the Epithelial-to-Mesenchymal Transition
Authors: de Reyniès Aurélien , Jaurand Marie-Claude , Renier Annie , Couchy Gabrielle , Hysi Ilir , Elarouci Nabila , Galateau-Sallé Françoise , Copin Marie-Christine , Hofman Paul , Cazes Aurélie , Andujar Pascal , Imbeaud Sandrine , Petel Fabien , Pairon Jean-Claude , Le Pimpec-Barthes Francoise , Zucman-Rossi Jessica , Jean Didier
Published: April 2023

Legends of Supplementary Figures and Tables PDF file 134K, This file contains the legends for supplementary figures S1-S7 and tables S1-S4
Supplementary Figure 1 from Prevailing Role of Contact Guidance in Intrastromal T-cell Trapping in Human Pancreatic Cancer
Authors: Hartmann Natalie , Giese Nathalia A. , Giese Thomas , Poschke Isabel , Offringa Rienk , Werner Jens , Ryschich Eduard
Published: April 2023

PDF file - 53KB, Phenotype of non-activated and activated T cells, representative FACS data of CD45RO/CCR7 (A) and CRs expression (B). Activated PBT displayed an effector/memory CD45RO+ CCR7- phenotype (A) and mainly expressed CXCR4 and CXCR3 (B).
Supplementary Table 1 from JMJD2B Promotes Epithelial–Mesenchymal Transition by Cooperating with β-Catenin and Enhances Gastric Cancer Metastasis
Authors: Zhao Li , Li Wenjuan , Zang Wen , Liu Zhifang , Xu Xia , Yu Han , Yang Qing , Jia Jihui
Published: April 2023

PDF file - 29K, Supplementary Table S1: Sequence of the oligonucleotides for siRNA construct-making, real-time PCR, and ChIP assays
Supplementary Figure 4 from JMJD2B Promotes Epithelial–Mesenchymal Transition by Cooperating with β-Catenin and Enhances Gastric Cancer Metastasis
Authors: Zhao Li , Li Wenjuan , Zang Wen , Liu Zhifang , Xu Xia , Yu Han , Yang Qing , Jia Jihui
Published: April 2023

PDF file - 2148K, Supplementary Figure 4 Status of proliferation/apoptosis in mouse lung metastasis samples.
Supplementary Table 2B-C from A Genome-Wide Aberrant RNA Splicing in Patients with Acute Myeloid Leukemia Identifies Novel Potential Disease Markers and Therapeutic Targets
Authors: Adamia Sophia , Haibe-Kains Benjamin , Pilarski Patrick M. , Bar-Natan Michal , Pevzner Samuel , Avet-Loiseau Herve , Lode Laurence , Verselis Sigitas , Fox Edward A. , Burke John , Galinsky Ilene , Dagogo-Jack Ibiayi , Wadleigh Martha , Steensma David P. , Motyckova Gabriela , Deangelo Daniel J. , Quackenbush John , Stone Richard , Griffin James D.
Published: April 2023

PDF file - 162K, Table S2b is a list of spliced oncogenes and tumor suppressors identified in AML patients and Table S2c is a list of genes spliced in both cohorts analyzed.
Supplementary Figures 1 - 2 from A Genome-Wide Aberrant RNA Splicing in Patients with Acute Myeloid Leukemia Identifies Novel Potential Disease Markers and Therapeutic Targets
Authors: Adamia Sophia , Haibe-Kains Benjamin , Pilarski Patrick M. , Bar-Natan Michal , Pevzner Samuel , Avet-Loiseau Herve , Lode Laurence , Verselis Sigitas , Fox Edward A. , Burke John , Galinsky Ilene , Dagogo-Jack Ibiayi , Wadleigh Martha , Steensma David P. , Motyckova Gabriela , Deangelo Daniel J. , Quackenbush John , Stone Richard , Griffin James D.
Published: April 2023

PDF file - 1538K, Figure S1 illustrates CD13 splice variant protein expression and Figure S2 shows representative electropherograms for DNA fragment analysis and capillary electrophoresis.
Supplementary Figure Legends from Preclinical and Early Clinical Evaluation of the Oral AKT Inhibitor, MK-2206, for the Treatment of Acute Myelogenous Leukemia
Authors: Konopleva Marina Y. , Walter Roland B. , Faderl Stefan H. , Jabbour Elias J. , Zeng Zhihong , Borthakur Gautam , Huang Xuelin , Kadia Tapan M. , Ruvolo Peter P. , Feliu Jennie B. , Lu Hongbo , Debose LaKiesha , Burger Jan A. , Andreeff Michael , Liu Wenbin , Baggerly Keith A. , Kornblau Steven M. , Doyle L. Austin , Estey Elihu H. , Kantarjian Hagop M.
Published: April 2023

PDF file - 62KB
Supplementary Figure 2B from Preclinical and Early Clinical Evaluation of the Oral AKT Inhibitor, MK-2206, for the Treatment of Acute Myelogenous Leukemia
Authors: Konopleva Marina Y. , Walter Roland B. , Faderl Stefan H. , Jabbour Elias J. , Zeng Zhihong , Borthakur Gautam , Huang Xuelin , Kadia Tapan M. , Ruvolo Peter P. , Feliu Jennie B. , Lu Hongbo , Debose LaKiesha , Burger Jan A. , Andreeff Michael , Liu Wenbin , Baggerly Keith A. , Kornblau Steven M. , Doyle L. Austin , Estey Elihu H. , Kantarjian Hagop M.
Published: April 2023

PDF file - 60KB, MK-2206 promotes accumulation of OCI-AML3 cells in the G1 phase of the cell cycle.
Supplementary Information from Autotaxin–Lysophosphatidic Acid Signaling Axis Mediates Tumorigenesis and Development of Acquired Resistance to Sunitinib in Renal Cell Carcinoma
Authors: Su Shih-Chi , Hu Xiaoxiao , Kenney Patrick A. , Merrill Megan M. , Babaian Kara N. , Zhang Xiu-Ying , Maity Tapati , Yang Shun-Fa , Lin Xin , Wood Christopher G.
Published: April 2023

PDF file 142K, Supplemental Materials and Methods, Supplemental Table S1-S2, and Supplemental Figure Legends Supplemental Table 1. Quantitative analysis of ENPP2 mRNA expression in tumor and normal renal endothelial cells. Endothelial cells from human RCC specimens (T) and their normal counterparts (N) were isolated from a single-cell suspension using anti-CD31-coated magnetic beads. Total RNA was prepared and real-time RT-PCR was performed for ENPP2 and GAPDH. Supplemental Table 2. The expression level of LPA1-4 is determined by real-time PCR. Part of results was confirmed by western blot. +++, average Ct < 31; +, average Ct ranges from 31 to 38; -, average Ct > 38 when average Ct of GAPDH ranges between 18 and 21, which is served as an internal control
Supplementary Figure 2 from Oncogenic Function of SCCRO5/DCUN1D5 Requires Its Neddylation E3 Activity and Nuclear Localization
Authors: Bommeljé Claire C. , Weeda Víola B. , Huang Guochang , Shah Kushyup , Bains Sarina , Buss Elizabeth , Shaha Manish , Gönen Mithat , Ghossein Ronald , Ramanathan Suresh Y. , Singh Bhuvanesh
Published: April 2023

PDF file - 840K, A, Western blot analysis of lysates of NIH-3T3 cells stably transfected with vector alone, SCCRO5, SCCRO5_∆1-10 or SCCRO5_D195N/A219R/D225N and probed with antibody against SCCRO5 or tubulin as a loading control. SCCRO5_∆1-10 is not detected as the antibody recognizes an epitope that included this region. B, Bar graph depicting results of qRT-PCR on the same cells as in A showing expression of transgenes.
Supplementary Figure 8 from Impairment of Glioma Stem Cell Survival and Growth by a Novel Inhibitor for Survivin–Ran Protein Complex
Authors: Guvenc Hacer , Pavlyukov Marat S. , Joshi Kaushal , Kurt Habibe , Banasavadi-Siddegowda Yeshavanth K. , Mao Ping , Hong Christopher , Yamada Ryosuke , Kwon Chang-Hyuk , Bhasin Deepak , Chettiar Somsundaram , Kitange Gaspar , Park In-Hee , Sarkaria Jann N. , Li Chenglong , Shakhparonov Mihail I. , Nakano Ichiro
Published: April 2023

PDF file - 881K, Therapy resistance gene expressions are increased with Temozolomide treatment (related to Figure 6)
Supplementary Figure 5 from Combined Immunostimulatory Monoclonal Antibodies Extend Survival in an Aggressive Transgenic Hepatocellular Carcinoma Mouse Model
Authors: Morales-Kastresana Aizea , Sanmamed Miguel F. , Rodriguez Inmaculada , Palazon Asis , Martinez-Forero Ivan , Labiano Sara , Hervas-Stubbs Sandra , Sangro Bruno , Ochoa Carmen , Rouzaut Ana , Azpilikueta Arantza , Bolaños Elixabet , Jure-Kunkel Maria , Gütgemann Ines , Melero Ignacio
Published: April 2023

PDF file - 2166K, Granzyme B, perforin and FasL are upregulated on CD8+ T cells after Combo3 treatment.
Supplementary Figure 1 from Combined Immunostimulatory Monoclonal Antibodies Extend Survival in an Aggressive Transgenic Hepatocellular Carcinoma Mouse Model
Authors: Morales-Kastresana Aizea , Sanmamed Miguel F. , Rodriguez Inmaculada , Palazon Asis , Martinez-Forero Ivan , Labiano Sara , Hervas-Stubbs Sandra , Sangro Bruno , Ochoa Carmen , Rouzaut Ana , Azpilikueta Arantza , Bolaños Elixabet , Jure-Kunkel Maria , Gütgemann Ines , Melero Ignacio
Published: April 2023

PDF file - 1818K, Activated T cells and tumor infiltrating lymphocytes express PD-1, B7-H1 (PD-L1), CD137 and OX40.
Supplementary Table S1 from T-cell Responses to Oncogenic Merkel Cell Polyomavirus Proteins Distinguish Patients with Merkel Cell Carcinoma from Healthy Donors
Authors: Lyngaa Rikke , Pedersen Natasja Wulff , Schrama David , Thrue Charlotte Albæk , Ibrani Dafina , Met Özcan , thor Straten Per , Nghiem Paul , Becker Jürgen C. , Hadrup Sine Reker
Published: April 2023

PDF file 41K, Information on MCC patients
Supplementary Figure S5 from T-cell Responses to Oncogenic Merkel Cell Polyomavirus Proteins Distinguish Patients with Merkel Cell Carcinoma from Healthy Donors
Authors: Lyngaa Rikke , Pedersen Natasja Wulff , Schrama David , Thrue Charlotte Albæk , Ibrani Dafina , Met Özcan , thor Straten Per , Nghiem Paul , Becker Jürgen C. , Hadrup Sine Reker
Published: April 2023

PDF file 43K, Alignment of MCPyV LTA
Supplementary Figure S1 from T-cell Responses to Oncogenic Merkel Cell Polyomavirus Proteins Distinguish Patients with Merkel Cell Carcinoma from Healthy Donors
Authors: Lyngaa Rikke , Pedersen Natasja Wulff , Schrama David , Thrue Charlotte Albæk , Ibrani Dafina , Met Özcan , thor Straten Per , Nghiem Paul , Becker Jürgen C. , Hadrup Sine Reker
Published: April 2023

PDF file 82K, MHC ELISA
Supplementary Figure Legend from ALKBH3 Contributes to Survival and Angiogenesis of Human Urothelial Carcinoma Cells through NADPH Oxidase and Tweak/Fn14/VEGF Signals
Authors: Shimada Keiji , Fujii Tomomi , Tsujikawa Kazutake , Anai Satoshi , Fujimoto Kiyohide , Konishi Noboru
Published: April 2023

PDF file, 95K.
Supplementary Figure 5 from ALKBH3 Contributes to Survival and Angiogenesis of Human Urothelial Carcinoma Cells through NADPH Oxidase and Tweak/Fn14/VEGF Signals
Authors: Shimada Keiji , Fujii Tomomi , Tsujikawa Kazutake , Anai Satoshi , Fujimoto Kiyohide , Konishi Noboru
Published: April 2023

PDF file, 66K, A correlation between positive percentages of ALKBH3 at initial diagnosis and pathological parameters including tumor multiplicity, tumor size and tumor recurrence within 5 years in human urothelial carcinomas.
Supplementary Figure 2 from Deciphering the Mechanisms of Tumorigenesis in Human Pancreatic Ductal Epithelial Cells
Authors: Chang Zhe , Li Zhongkui , Wang Xiaoyang , Kang Ya'an , Yuan Yuhui , Niu Jiangong , Wang Huamin , Chatterjee Deyali , Fleming Jason B. , Li Min , Abbruzzese James L. , Chiao Paul J.
Published: April 2023

PDF file - 169K, Supplementary Fig. 2. Cell migration and invasion abilities of HPDE cells with expression of mutant K-ras, Her2, p16/p14shRNA, and Smad4shRNA.
Supplementary Methods from Notch Pathway Activity Identifies Cells with Cancer Stem Cell–like Properties and Correlates with Worse Survival in Lung Adenocarcinoma
Authors: Hassan Khaled A. , Wang Luo , Korkaya Hasan , Chen Guoan , Maillard Ivan , Beer David G. , Kalemkerian Gregory P. , Wicha Max S.
Published: April 2023

PDF file - 84K, Immunohistochemistry and PCR assays methodology.
Supplementary Figure 7 from Notch Pathway Activity Identifies Cells with Cancer Stem Cell–like Properties and Correlates with Worse Survival in Lung Adenocarcinoma
Authors: Hassan Khaled A. , Wang Luo , Korkaya Hasan , Chen Guoan , Maillard Ivan , Beer David G. , Kalemkerian Gregory P. , Wicha Max S.
Published: April 2023

PDF file - 59K, Notch1 receptor mutation analysis in multiple NSCLC cell lines.
Supplementary Table S4 from Preclinical Antitumor Activity of Cabazitaxel, a Semisynthetic Taxane Active in Taxane-Resistant Tumors
Authors: Vrignaud Patricia , Sémiond Dorothée , Lejeune Pascale , Bouchard Hervé , Calvet Loreley , Combeau Cecile , Riou Jean-François , Commerçon Alain , Lavelle François , Bissery Marie-Christine
Published: April 2023

Supplementary Table S4 - PDF file 55K, Schedule of cabazitaxel administration in C3H/HeN female mice bearing mammary adenocarcinoma MA17/A or MA16/C tumor
Supplementary Figure 5 from Notch Pathway Activity Identifies Cells with Cancer Stem Cell–like Properties and Correlates with Worse Survival in Lung Adenocarcinoma
Authors: Hassan Khaled A. , Wang Luo , Korkaya Hasan , Chen Guoan , Maillard Ivan , Beer David G. , Kalemkerian Gregory P. , Wicha Max S.
Published: April 2023

PDF file - 102K, Xenograft tumor growth curves of NCI-H1299 cell lines, in mice treated with MRK003, docetaxel, and combination with evidence of blocking Notch activity with MRK003 treatment.
Supplementary Table S2 from Preclinical Antitumor Activity of Cabazitaxel, a Semisynthetic Taxane Active in Taxane-Resistant Tumors
Authors: Vrignaud Patricia , Sémiond Dorothée , Lejeune Pascale , Bouchard Hervé , Calvet Loreley , Combeau Cecile , Riou Jean-François , Commerçon Alain , Lavelle François , Bissery Marie-Christine
Published: April 2023

Supplementary Table S2 - PDF file 53K, Microtubule parameters analyzed by PCR for B16 and B16/TXT tumors
Supplementary Table S1 from Preclinical Antitumor Activity of Cabazitaxel, a Semisynthetic Taxane Active in Taxane-Resistant Tumors
Authors: Vrignaud Patricia , Sémiond Dorothée , Lejeune Pascale , Bouchard Hervé , Calvet Loreley , Combeau Cecile , Riou Jean-François , Commerçon Alain , Lavelle François , Bissery Marie-Christine
Published: April 2023

Supplementary Table S1 - PDF file 60K, Characterization of docetaxel-resistant human breast carcinoma (Calc18/TXT) and murine leukemia (P388/TXT) cell lines
Supplementary Figure 2 from Notch Pathway Activity Identifies Cells with Cancer Stem Cell–like Properties and Correlates with Worse Survival in Lung Adenocarcinoma
Authors: Hassan Khaled A. , Wang Luo , Korkaya Hasan , Chen Guoan , Maillard Ivan , Beer David G. , Kalemkerian Gregory P. , Wicha Max S.
Published: April 2023

PDF file - 357K, NSCLC cell lines transduced with Notch reporter.
Supplementary Material from Effects of Early Chemotherapeutic Treatment on Learning in Adolescent Mice: Implications for Cognitive Impairment and Remediation in Childhood Cancer Survivors
Authors: Bisen-Hersh Emily B. , Hineline Philip N. , Walker Ellen A.
Published: April 2023

Supplementary Material PDF file 118K, Detailed description of the conditional discrimination procedure, as well as group composition for each behavioral task
Supplementary Figure Legend from A Phase I Trial of Dasatinib, an Src-Family Kinase Inhibitor, in Combination with Paclitaxel and Carboplatin in Patients with Advanced or Recurrent Ovarian Cancer
Authors: Secord Angeles Alvarez , Teoh Deanna K. , Barry William T. , Yu Miao , Broadwater Gloria , Havrilesky Laura J. , Lee Paula S. , Berchuck Andrew , Lancaster Johnathan , Wenham Robert M.
Published: April 2023

PDF file, 48K.
Supplementary Fig S1 from Effects of Early Chemotherapeutic Treatment on Learning in Adolescent Mice: Implications for Cognitive Impairment and Remediation in Childhood Cancer Survivors
Authors: Bisen-Hersh Emily B. , Hineline Philip N. , Walker Ellen A.
Published: April 2023

Supplementary Fig S1 PDF file 26K, Validation of the conditional discrimination procedure using scopolamine
Supplementary Figure 2 from A Phase I Trial of Dasatinib, an Src-Family Kinase Inhibitor, in Combination with Paclitaxel and Carboplatin in Patients with Advanced or Recurrent Ovarian Cancer
Authors: Secord Angeles Alvarez , Teoh Deanna K. , Barry William T. , Yu Miao , Broadwater Gloria , Havrilesky Laura J. , Lee Paula S. , Berchuck Andrew , Lancaster Johnathan , Wenham Robert M.
Published: April 2023

PDF file, 130K, Heatmaps and Safe Plots.
Supplementary Figure 6 from Small-Molecule RA-9 Inhibits Proteasome-Associated DUBs and Ovarian Cancer In Vitro and In Vivo via Exacerbating Unfolded Protein Responses
Authors: Coughlin Kathleen , Anchoori Ravi , Iizuka Yoshie , Meints Joyce , MacNeill Lauren , Vogel Rachel Isaksson , Orlowski Robert Z. , Lee Michael K. , Roden Richard B.S. , Bazzaro Martina
Published: April 2023

PDF file - 122KB, Effect of RA-9 treatment on total body weight.
Supplementary Figure 5 from Small-Molecule RA-9 Inhibits Proteasome-Associated DUBs and Ovarian Cancer In Vitro and In Vivo via Exacerbating Unfolded Protein Responses
Authors: Coughlin Kathleen , Anchoori Ravi , Iizuka Yoshie , Meints Joyce , MacNeill Lauren , Vogel Rachel Isaksson , Orlowski Robert Z. , Lee Michael K. , Roden Richard B.S. , Bazzaro Martina
Published: April 2023

PDF file - 504KB, RA-9 inhibits tumor growth in vivo.
Supplementary Figure 3 from Small-Molecule RA-9 Inhibits Proteasome-Associated DUBs and Ovarian Cancer In Vitro and In Vivo via Exacerbating Unfolded Protein Responses
Authors: Coughlin Kathleen , Anchoori Ravi , Iizuka Yoshie , Meints Joyce , MacNeill Lauren , Vogel Rachel Isaksson , Orlowski Robert Z. , Lee Michael K. , Roden Richard B.S. , Bazzaro Martina
Published: April 2023

PDF file - 732KB, UPR stress levels in ovarian surface epithelial cells (OSEs).
Supplementary Figure 3 from Enhancement of Human Cancer Cell Motility and Invasiveness by Anaphylatoxin C5a via Aberrantly Expressed C5a Receptor (CD88)
Authors: Nitta Hidetoshi , Wada Yoshihiro , Kawano Yoshiaki , Murakami Yoji , Irie Atsushi , Taniguchi Keisuke , Kikuchi Ken , Yamada Gen , Suzuki Kentaro , Honda Jiro , Wilson-Morifuji Masayo , Araki Norie , Eto Masatoshi , Baba Hideo , Imamura Takahisa
Published: April 2023

PDF file - 24K, Effects of C5aR antagonist and MMP inhibitors on cancer cell invasion
Supplementary Figure 2 from Small-Molecule RA-9 Inhibits Proteasome-Associated DUBs and Ovarian Cancer In Vitro and In Vivo via Exacerbating Unfolded Protein Responses
Authors: Coughlin Kathleen , Anchoori Ravi , Iizuka Yoshie , Meints Joyce , MacNeill Lauren , Vogel Rachel Isaksson , Orlowski Robert Z. , Lee Michael K. , Roden Richard B.S. , Bazzaro Martina
Published: April 2023

PDF file - 322KB, Ovarian cancer cells sensitivity to cisplatin and to RA 9/cisplatin combination.
Supplementary Figure 2, Video 2 from Enhancement of Human Cancer Cell Motility and Invasiveness by Anaphylatoxin C5a via Aberrantly Expressed C5a Receptor (CD88)
Authors: Nitta Hidetoshi , Wada Yoshihiro , Kawano Yoshiaki , Murakami Yoji , Irie Atsushi , Taniguchi Keisuke , Kikuchi Ken , Yamada Gen , Suzuki Kentaro , Honda Jiro , Wilson-Morifuji Masayo , Araki Norie , Eto Masatoshi , Baba Hideo , Imamura Takahisa
Published: April 2023

AVI file - 15500K, Time-lapse video analysis-C5aR(-)C5a(+)
Supplementary Figure 2, Video 1 from Enhancement of Human Cancer Cell Motility and Invasiveness by Anaphylatoxin C5a via Aberrantly Expressed C5a Receptor (CD88)
Authors: Nitta Hidetoshi , Wada Yoshihiro , Kawano Yoshiaki , Murakami Yoji , Irie Atsushi , Taniguchi Keisuke , Kikuchi Ken , Yamada Gen , Suzuki Kentaro , Honda Jiro , Wilson-Morifuji Masayo , Araki Norie , Eto Masatoshi , Baba Hideo , Imamura Takahisa
Published: April 2023

AVI file - 13904K, Time-lapse video analysis-C5aR(-)C5a(-)
Supplementary Table 2 from Vaccination with Dendritic Cell/Tumor Fusions following Autologous Stem Cell Transplant Induces Immunologic and Clinical Responses in Multiple Myeloma Patients
Authors: Rosenblatt Jacalyn , Avivi Irit , Vasir Baldev , Uhl Lynne , Munshi Nikhil C. , Katz Tami , Dey Bimalangshu R. , Somaiya Poorvi , Mills Heidi , Campigotto Federico , Weller Edie , Joyce Robin , Levine James D. , Tzachanis Dimitrios , Richardson Paul , Laubach Jacob , Raje Noopur , Boussiotis Vassiliki , Yuan Yan Emily , Bisharat Lina , Held Viki , Rowe Jacob , Anderson Kenneth , Kufe Donald , Avigan David
Published: April 2023

PDF file - 522K, Percentage of CD8+T cells recognizing MUC1 tetramer in HLA 2.1+ patients.
Supplementary Table 1 from A Novel Therapeutic Regimen to Eradicate Established Solid Tumors with an Effective Induction of Tumor-Specific Immunity
Authors: Tysome James R. , Li Xiaozhu , Wang Shengdian , Wang Pengju , Gao Dongling , Du Pan , Chen Dong , Gangeswaran Rathi , Chard Louisa S. , Yuan Ming , Alusi Ghassan , Lemoine Nicholas R. , Wang Yaohe
Published: April 2023

PDF file - 49K, Primers and probes used for qPCR
Supplementary Figure 4 from A Novel Therapeutic Regimen to Eradicate Established Solid Tumors with an Effective Induction of Tumor-Specific Immunity
Authors: Tysome James R. , Li Xiaozhu , Wang Shengdian , Wang Pengju , Gao Dongling , Du Pan , Chen Dong , Gangeswaran Rathi , Chard Louisa S. , Yuan Ming , Alusi Ghassan , Lemoine Nicholas R. , Wang Yaohe
Published: April 2023

PDF file - 31K, Superior antitumor efficacy by sequential use of oncolytic adenovirus and vaccinia virus is mediated by CD3+ T cells in the immunocompetent Syrian hamster HAK
Supplementary Table 2 from The Use of Quantitative Real-Time Reverse Transcriptase PCR for 5′ and 3′ Portions of ALK Transcripts to Detect ALK Rearrangements in Lung Cancers
Authors: Wang Rui , Pan Yunjian , Li Chenguang , Hu Haichuan , Zhang Yang , Li Hang , Luo Xiaoyang , Zhang Jie , Fang Zhaoyuan , Li Yuan , Shen Lei , Ji Hongbin , Garfield David , Sun Yihua , Chen Haiquan
Published: April 2023

PDF file, 37K, Patient Characteristics.
Supplementary Figure 3 from A Novel Therapeutic Regimen to Eradicate Established Solid Tumors with an Effective Induction of Tumor-Specific Immunity
Authors: Tysome James R. , Li Xiaozhu , Wang Shengdian , Wang Pengju , Gao Dongling , Du Pan , Chen Dong , Gangeswaran Rathi , Chard Louisa S. , Yuan Ming , Alusi Ghassan , Lemoine Nicholas R. , Wang Yaohe
Published: April 2023

PDF file - 174K, Efficiency of the monoclonal antibody 4F11 in depleting CD3+ T-cells in vivo
Supplementary Figures 1 - 2, Tables 1 - 6 from Murine Microenvironment Metaprofiles Associate with Human Cancer Etiology and Intrinsic Subtypes
Authors: Nguyen David H. , Fredlund Erik , Zhao Wei , Perou Charles M. , Balmain Allan , Mao Jian-Hua , Barcellos-Hoff Mary Helen
Published: April 2023

PDF file - 274K, Table S1. SigClust classification of 56 Trp53 null mouse mammary tumors. Table S2 Genes in the 323-irradiated host signature Table S3 Genes of the 72-gene centroid Table S4 Gene clusters that are induced within the subgroups of Figure 4A. Table S5. Biological functions of 323-IHC genes Table S6 Gene lists for gene clusters in Figure 5A and 6C. Figure S1. The irradiated host signature detects radiation-preceded human cancers. Figure S2 (Goes with Figure 4)
Supplementary Figure 5 from The Nedd8-Activating Enzyme Inhibitor MLN4924 Thwarts Microenvironment-Driven NF-κB Activation and Induces Apoptosis in Chronic Lymphocytic Leukemia B Cells
Authors: Godbersen J. Claire , Humphries Leigh Ann , Danilova Olga V. , Kebbekus Peter E. , Brown Jennifer R. , Eastman Alan , Danilov Alexey V.
Published: April 2023

BMS-345541 leads to Bim upregulation in CLL. CLL cells (N=3) were co-cultured with CD40L-expressing stroma for 24 hours, followed by incubation with 2 - 12 ÃŽÂ¼M BMS-345541 or vehicle control for 24 h. Cells were lysed and subjected to immunoblotting. 1 out of 3 representative images is shown.
Supplementary Figure 4 from The Nedd8-Activating Enzyme Inhibitor MLN4924 Thwarts Microenvironment-Driven NF-κB Activation and Induces Apoptosis in Chronic Lymphocytic Leukemia B Cells
Authors: Godbersen J. Claire , Humphries Leigh Ann , Danilova Olga V. , Kebbekus Peter E. , Brown Jennifer R. , Eastman Alan , Danilov Alexey V.
Published: April 2023

MLN4924 leads to downregulation of NFÃŽÂºB activity in a dose-dependent manner. (A) MLN4924 leads to downregulation of CXCR5 in CLL. CLL cells (N=9) were co-cultured with CD40L-expressing stroma for 24 hours, followed by incubation with 1 ÃŽÂ¼M MLN4924 or vehicle control for 24 h. Total RNA was isolated from CD19+ CLL B-cells, reverse-transcribed and subjected to real-time PCR with the indicated probes (in duplicates). Results were normalized to 18S levels. (B-C) CLL cells (N=4) were co-cultured with CD40L-expressing stroma for 24 hours, followed by incubation with 0.25 or 1 ÃŽÂ¼M MLN4924 or vehicle control for another 24 h. Nuclear protein fractions were isolated and p50 and p65 activity was measured by ELISA as per manufacturer's instructions (B). Total RNA was reverse-transcribed (C) and subjected to real-time PCR with the indicated probes (in duplicates). Results were normalized to 18S levels. Measurements were normalized to vehicle control and reported as a fold change. * - p<0.05 and ** - p<0.01 compared to untreated control.
Supplementary Figures 1-7 from Coadministration of Epithelial Junction Opener JO-1 Improves the Efficacy and Safety of Chemotherapeutic Drugs
Authors: Beyer Ines , Cao Hua , Persson Jonas , Song Hui , Richter Maximilian , Feng Qinghua , Yumul Roma , van Rensburg Ruan , Li Zongyi , Berenson Ronald , Carter Darrick , Roffler Steve , Drescher Charles , Lieber André
Published: April 2023

PDF file - 441K, Suppl. Figure 1. DSG2 immunohistochemistry on sections of human breast cancer biopsies.Suppl. Figure 2. JO-1 improves efficacy of chemotherapy agents. Suppl. Figure 3. Effect of JO-1 on Doxil and cisplatin in an ovarian cancer model.Suppl. Figure 4. JO-1 in liver and spleen.Suppl. Figure 5. Serum clearance of JO-1. Suppl. Figure 6. JO-1 safety studies in hDSG2 transgenic mice. Suppl. Figure 7. Circulating tumor cells.
Supplementary Figure Legends from Long-term Vaccination with Multiple Peptides Derived from Cancer-Testis Antigens Can Maintain a Specific T-cell Response and Achieve Disease Stability in Advanced Biliary Tract Cancer
Authors: Aruga Atsushi , Takeshita Nobuhiro , Kotera Yoshihito , Okuyama Ryuji , Matsushita Norimasa , Ohta Takehiro , Takeda Kazuyoshi , Yamamoto Masakazu
Published: April 2023

PDF File - 23K, Legends for Figures 1 and 2.
Supplementary table 4 from Altered DNA Methylation Landscapes of Polycomb-Repressed Loci Are Associated with Prostate Cancer Progression and ERG Oncogene Expression in Prostate Cancer
Authors: Kron Ken , Trudel Dominique , Pethe Vaijayanti , Briollais Laurent , Fleshner Neil , van der Kwast Theodorus , Bapat Bharati
Published: April 2023

Supplementary table 4 XLSX file 146K,Functional annotaion of significant DMRs from GS analyses using DAVID
Supplementary Table 4 from miR-187 Is an Independent Prognostic Factor in Breast Cancer and Confers Increased Invasive Potential In Vitro
Authors: Mulrane Laoighse , Madden Stephen F. , Brennan Donal J. , Gremel Gabriela , McGee Sharon F. , McNally Sara , Martin Finian , Crown John P. , Jirström Karin , Higgins Desmond G. , Gallagher William M. , O'Connor Darran P.
Published: April 2023

PDF file - 73K, Association of clinicopathological characteristics of tumours with miR-187 expression in Cohort 2 (n=470) using Pearson's chi-squared test
Supplementary Table 2 from miR-187 Is an Independent Prognostic Factor in Breast Cancer and Confers Increased Invasive Potential In Vitro
Authors: Mulrane Laoighse , Madden Stephen F. , Brennan Donal J. , Gremel Gabriela , McGee Sharon F. , McNally Sara , Martin Finian , Crown John P. , Jirström Karin , Higgins Desmond G. , Gallagher William M. , O'Connor Darran P.
Published: April 2023

PDF file - 65K, miRNAs associated with poor outcome in breast cancer patient cohorts
Supplementary Figure 1 from Targeting the CD20 and CXCR4 Pathways in Non-Hodgkin Lymphoma with Rituximab and High-Affinity CXCR4 Antagonist BKT140
Authors: Beider Katia , Ribakovsky Elena , Abraham Michal , Wald Hanna , Weiss Lola , Rosenberg Evgenia , Galun Eithan , Avigdor Abraham , Eizenberg Orly , Peled Amnon , Nagler Arnon
Published: April 2023

Supplementary Figure 1 - PDF file 118K, CXCR4 expression in NHL cells
Supplementary Figure 2 from A Purine Scaffold HSP90 Inhibitor BIIB021 Has Selective Activity against KSHV-Associated Primary Effusion Lymphoma and Blocks vFLIP K13-Induced NF-κB
Authors: Gopalakrishnan Ramakrishnan , Matta Hittu , Chaudhary Preet M.
Published: April 2023

PDF file, 985K, Effect of BIIB021 on the effect of lytic proteins (RTA and vIL-6)induced by TPA in BC-1 and BC-3 cells were given in this file.
Supplementary Figure 5 from Combined Targeting of STAT3/NF-κB/COX-2/EP4 for Effective Management of Pancreatic Cancer
Authors: Gong Jingjing , Xie Jianping , Bedolla Roble , Rivas Paul , Chakravarthy Divya , Freeman James W. , Reddick Robert , Kopetz Scott , Peterson Amanda , Wang Huamin , Fischer Susan M. , Kumar Addanki P.
Published: April 2023

PDF file - 1241KB, Nx treatment inhibits Cox-2 levels and activity.
Supplementary Figure 3 from Combined Targeting of STAT3/NF-κB/COX-2/EP4 for Effective Management of Pancreatic Cancer
Authors: Gong Jingjing , Xie Jianping , Bedolla Roble , Rivas Paul , Chakravarthy Divya , Freeman James W. , Reddick Robert , Kopetz Scott , Peterson Amanda , Wang Huamin , Fischer Susan M. , Kumar Addanki P.
Published: April 2023

PDF file - 1727KB, Nx treatment reduces protein levels of p65, p50 and pStta3 in Ras transformed cells and lower exposure blot of data presented in Fig 2.
Supplementary Figures 1 - 6 and Tables 1 - 10 from Cross-talk between EphA2 and BRaf/CRaf Is a Key Determinant of Response to Dasatinib
Authors: Huang Jie , Hu Wei , Bottsford-Miller Justin , Liu Tao , Han Hee Dong , Zand Behrouz , Pradeep Sunila , Roh Ju-Won , Thanapprapasr Duangmani , Dalton Heather J. , Pecot Chad V. , Rupaimoole Rajesh , Lu Chunhua , Fellman Bryan , Urbauer Diana , Kang Yu , Jennings Nicholas B. , Huang Li , Deavers Michael T. , Broaddus Russell , Coleman Robert L. , Sood Anil K.
Published: April 2023

PDF file - 930KB, The supplementary file includes: Figure S1. Effects of dasatinib on uterine and ovarian cancer cells. Figure S2. Effects of dasatinib based on PTEN status. Figure S3. RPPA analysis of expression levels of 176 proteins in uterine cancer cells treated with dasatinib, paclitaxel, or both. Figure S4. Effect of dasatinib on selected proteins in uterine cancer cell lines. Figure S5. Effect of dasatinib on uterine cancer cell lines with or without EphA2 silencing. Figure S6. In vivo effects of dasatinib and paclitaxel on mouse models of uterine carcinoma. Table S1. Candidate predictive markers for response to dasatinib in uterine cancer. Table S2. Basal expression levels of putative dasatinib response markers in human normal uterine and uterine cancer samples. Table S3. Proteins that differed among controls and treated SPEC-2 cells Table S4. Mean fold change of proteins in SPEC-2 cell line Table S5. Proteins that differed among controls and treated SKUT-2 cells Table S6. Mean fold change of proteins in SKUT-2 cell line Table S7. Proteins that differed among controls and treated HEC1-A cells Table S8. Mean fold change of proteins in HEC1-A cell line Table S9. Proteins that differed among controls and treated Ishikawa cells Table S10. Mean fold change of proteins in Ishikawa cell line.
Supplementary Figures 4 - 8 from Arylsulfonamide KCN1 Inhibits In Vivo Glioma Growth and Interferes with HIF Signaling by Disrupting HIF-1α Interaction with Cofactors p300/CBP
Authors: Yin Shaoman , Kaluz Stefan , Devi Narra S. , Jabbar Adnan A. , de Noronha Rita G. , Mun Jiyoung , Zhang Zhaobin , Boreddy Purushotham R. , Wang Wei , Wang Zhibo , Abbruscato Thomas , Chen Zhengjia , Olson Jeffrey J. , Zhang Ruiwen , Goodman Mark M. , Nicolaou K.C. , Van Meir Erwin G.
Published: April 2023

PDF file, 591K, Supplementary Figure 4. KCN1 inhibits the growth of pre-established human glioblastoma s.c. xenografts. Supplementary Figure 5. Effect of KCN1 treatment on mice weight. Supplementary Figure 6. Chronic systemic KCN1 administration shows little effect on major organs, except liver. Supplementary Figure 7. Effect of KCN1 on the survival of mice with orthotopic (intracranial) brain tumor models. Supplementary Figure 8. Permeability coefficients (PC) of KCN1 calculated from the transfer across monolayers of brain endothelial cells.
Supplementary Figures 1 - 3 from Arylsulfonamide KCN1 Inhibits In Vivo Glioma Growth and Interferes with HIF Signaling by Disrupting HIF-1α Interaction with Cofactors p300/CBP
Authors: Yin Shaoman , Kaluz Stefan , Devi Narra S. , Jabbar Adnan A. , de Noronha Rita G. , Mun Jiyoung , Zhang Zhaobin , Boreddy Purushotham R. , Wang Wei , Wang Zhibo , Abbruscato Thomas , Chen Zhengjia , Olson Jeffrey J. , Zhang Ruiwen , Goodman Mark M. , Nicolaou K.C. , Van Meir Erwin G.
Published: April 2023

PDF file, 285K, Supplementary Figure 1. Synthetic scheme and purity of KCN1 3,4-dimethoxy-N-(2,2-dimethyl-2H-chromen-6-yl)methyl-N-phenylbenzenesulfonamide. Supplementary Figure 2. KCN1 is chemically stable in cell culture medium under normoxic or hypoxic conditions. Supplementary Figure 3. Effect of KCN1 in the NCI-60 Tumor Cell Line Screen.
Supplementary Table 1 from Therapeutic Efficacy of an Fc-Enhanced TCR-like Antibody to the Intracellular WT1 Oncoprotein
Authors: Veomett Nicholas , Dao Tao , Liu Hong , Xiang Jingyi , Pankov Dmitry , Dubrovsky Leonid , Whitten Joseph A. , Park Sun-Mi , Korontsvit Tatyana , Zakhaleva Victoria , Casey Emily , Curcio Michael , Kharas Michael G. , O'Reilly Richard J. , Liu Cheng , Scheinberg David A.
Published: April 2023

PDF file - 38KB, Histopathologic report from ESKM- or isotype control human IgG1-treated HLA-A*02:01+ transgenic mice.
Supplementary Figure 1 from Therapeutic Efficacy of an Fc-Enhanced TCR-like Antibody to the Intracellular WT1 Oncoprotein
Authors: Veomett Nicholas , Dao Tao , Liu Hong , Xiang Jingyi , Pankov Dmitry , Dubrovsky Leonid , Whitten Joseph A. , Park Sun-Mi , Korontsvit Tatyana , Zakhaleva Victoria , Casey Emily , Curcio Michael , Kharas Michael G. , O'Reilly Richard J. , Liu Cheng , Scheinberg David A.
Published: April 2023

PDF file - 78KB, ESKM has a modified Fc glycosylation pattern, altering binding to FcgammaRs but not to the RMF/A2 target. Where applicable, data points are averages of each group, and error bars represent SEM. (A) Comparison of the oligosaccharide profile of ESK1 and ESKM. Peak assignment is based on the retention time and the monosaccharide composition analysis. G# indicates the number of terminal galactoses, F indicates presence of core fucose, Hex5GlcNAc2 denotes (GlcNAc)2 core with terminal Hexose 5 glycan structure (terminating in mannose and/or glucose). (B-C) Representative binding curves of ESK1 and ESKM against human FcgammaRI, FcgammaRIIa, FcgammaRIIb, FcgammaRIIIa - 158V, FcgammaRIIIa -158F, and FcRn (B), and mouse FcgammaRIIb and FcgammaRIV (C). (D) 125 I-labeled ESK1 and ESKM mAbs were titrated against JMN cells. All curves were fit with a non-linear single-site total binding saturation curve, and Kd was calculated using Prism software.